Intensity Therapeutics(INTS) - 2023 Q4 - Annual Results

Exhibit 99.1 Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update Shelton, CT, March 14, 2024 – Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces full year 2023 financial results and provides a review of 2023 a ...